Aakaar Medical Technologies Q2 FY27 Share Price & Earnings Call Analysis
- Market cap
- ₹105 Cr
- P/E
- 9.59
- ROE
- 17.07%
- PEG
- 0.21
- Price to sales
- 1.23
- Debt to equity
- 0.33
- 52W high / low
- ₹84.0 / ₹48.0
- Sales growth (5Y)
- 40.02%
- EBITDA margin
- 18.57%
- Net profit margin
- 9.92%
- Promoter holding
- 67.05%
- Sales (last year)
- ₹85 Cr
Incorporated in June 2013, Aakaar Medical Technologies Limited is an aesthetic medical company that offers a diverse selection of specialized cosmetic products and devices.[1]
Guidance scorecard · Q2 FY27 call
What Aakaar Medical's management guided
and where it ranks in Personal Products
Personal Products
RevenueQ2 FY27 call
20–40%- Aakaar Medical Technologies targets a CAGR of around 36% in revenue growth going forward, with optimism of reaching 50% CAGR in the coming years.
- The company aims to regain lost momentum from prior years and sustain profitable year-on-year growth.
- Expansion plans include increasing distribution network from 40 to 100 distributors over two years to improve last-mile delivery and collections.
- Growth is expected from enhanced sales of both imported and Aakaar's own brands, with the latter projected to constitute about 36-37% of revenue by year-end.
- New initiatives like FotoFinder device sales and the Xelix franchise model are expected to add to revenue.
- Aakaar plans to launch a direct-to-consumer website to capture revenue leakage and boost brand sales and margins.
2 more points from Aakaar Medical's call on revenue
Create a free account to keep reading this call
MarginsQ2 FY27 call
FlatSee what Aakaar Medical said on margins — free account, 30 seconds.
CapexQ2 FY27 call
Planned- Aakaar Medical Technologies has already allocated funds for R&D over multiple periods for product development, including the Xelix hair transplant device.
- The Xelix hair transplant device is nearing completion with the prototype finalized and nearing the test license filing stage with CDSCO.
- No significant new capex or large-scale manufacturing investments currently planned; focus remains on sales and marketing.
- Own manufacturing is considered only if there is a unique product proposition requiring proprietary control, otherwise third-party or loan license manufacturing is preferred.
2 more points from Aakaar Medical's call on capex
Create a free account to keep reading this call
FundraisingQ2 FY27 call
See what Aakaar Medical said on fundraising — free account, 30 seconds.
Order bookQ2 FY27 call
- The company has seen strong revenue growth, with H1 FY27 revenue at INR 43.72 crores, up 72.64% YoY.
- They are confident of maintaining a CAGR of around 36% going forward.
- Several deals in pipeline related to FotoFinder devices could contribute to achieving annual targets.
- The Xelix clinic network has onboarded 70+ doctors; targeting 100 doctors soon before scaling marketing and lead generation.
2 more points from Aakaar Medical's call on the order book
Create a free account to keep reading this call
Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Potential multibaggers · Q2 FY27
Potential multibaggers in Personal Products
on management's own guidance
- Strong growth2
- Strong growth1
- Honasa Consumer LtdGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Personal Products companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹1,858 Cr | 55.5 | |
| 2 | 40%+ | Flat | ₹408 Cr | 36.4 | |
| 3 | Honasa Consumer Ltd | 20–40% | Up 0–2% | ₹14,422 Cr | 57.1 |
| 4 | Aakaar MedicalThis stock | 20–40% | Flat | ₹101 Cr | 9.2 |
| 5 | 10–20% | Flat | ₹86,892 Cr | 40.9 | |
| 6 | 10–20% | Flat | ₹64,856 Cr | 32.7 |
Sign up free to see every company in the sector ranking and track Aakaar Medical.
Pro shows every company guiding 40%+ revenue growth →Full Personal Products rankingFinancials of Aakaar Medical
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Shareholder Pattern
Aakaar Medical
Shareholding breakup across reporting periods.
| Jun 2025 | Sep 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|
| Promoters + | 67.01% | 67.01% | 67.05% | 67.05% |
| FIIs + | 1.87% | 0.50% | 0.00% | 0.00% |
| DIIs + | 12.33% | 10.73% | 11.17% | 10.13% |
| Public + | 18.79% | 21.77% | 21.78% | 22.82% |
| No. of Shareholders | 920 | 603 | 550 | 558 |
Financials of Aakaar Medical
Quarterly Results
Quarter-by-quarter operating performance
Financials of Aakaar Medical
Profit & Loss
Annual income statement trend
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Sales + | 23 | 12 | 19 | 33 | 46 | 62 | 67 | 85 |
| Sales growth | -46% | +57% | +68% | +41% | +34% | +9% | +44% | |
| Expenses + | 20 | 12 | 17 | 29 | 41 | 52 | 57 | 70 |
| Operating Profit | 3 | 1 | 2 | 4 | 5 | 10 | 10 | 16 |
| OPM % | 13% | 7% | 12% | 11% | 11% | 16% | 15% | 19% |
| Other Income + | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Interest | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 2 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 2 | 1 | 2 | 3 | 4 | 8 | 9 | 15 |
| Tax % | 27% | 29% | 26% | 31% | 26% | 26% | 28% | |
| Net Profit + | 2 | 1 | 2 | 2 | 3 | 6 | 7 | 11 |
| EPS in Rs | 2.01 | 0.59 | 1.78 | 2.36 | 3.15 | 5.79 | 4.69 | 7.74 |
| Dividend Payout % | 0% | 0% | 35% | 24% | 0% | 0% | 0% |
Financials of Aakaar Medical
Balance Sheet
Capital structure and asset base
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.10 | 0.10 | 0.70 | 0.70 | 0.70 | 10 | 14 | 14 |
| Reserves | 7 | 7 | 7 | 9 | 12 | 13 | 40 | 44 |
| Borrowings + | 6 | 4 | 4 | 6 | 15 | 23 | 19 | 19 |
| Other Liabilities + | 4 | 3 | 6 | 8 | 6 | 8 | 6 | 12 |
| Total Liabilities | 16 | 14 | 18 | 23 | 34 | 54 | 79 | 88 |
| Fixed Assets + | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets + | 16 | 14 | 18 | 23 | 34 | 54 | 79 | 87 |
| Total Assets | 16 | 14 | 18 | 23 | 34 | 54 | 79 | 88 |
Financials of Aakaar Medical
Cash Flows
Operating, investing and financing cash movement
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | -0 | 4 | 0 | -3 | -8 | -5 | -8 |
| Cash from Investing Activity + | 0 | 0 | -0 | -0 | -0 | -0 | 0 |
| Cash from Financing Activity + | 0 | -2 | -1 | 1 | 8 | 11 | 19 |
| Net Cash Flow | 0 | 3 | -1 | -2 | 0 | 5 | 10 |
| Free Cash Flow | -0 | 4 | 0 | -3 | -8 | -5 | -9 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 10% | 503% | 47% | -54% | -136% | -35% | -59% |
Financials of Aakaar Medical
Ratios
Working capital efficiency and return ratios
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 118 | 136 | 104 | 114 | 129 | 166 | 203 |
| Inventory Days | 234 | 366 | 282 | 274 | 247 | 202 | 256 |
| Days Payable | 28 | 99 | 65 | 62 | 32 | 49 | 24 |
| Cash Conversion Cycle | 324 | 403 | 321 | 326 | 344 | 320 | 434 |
| Working Capital Days | 189 | 238 | 105 | 102 | 94 | 97 | 199 |
| ROCE % | 8% | 21% | 26% | 23% | 27% | 18% |
Guidance history
How Aakaar Medical's guidance has moved, call by call
| Call | Revenue | Margins | Capex | Fundraising | Order book |
|---|---|---|---|---|---|
| Q2 FY27 call → | 20–40% | Flat | Planned | — | — |
| Q4 FY26 call → | 20–40% | Flat | None planned | — | — |
| Q2 FY26 call → | 20–40% | Flat | Planned | — | — |
What management guided on each call, newest first. Not investment advice, and not a forecast of returns.
Continue your research
What Aakaar Medical's management said in earlier quarters
Others in Personal Products this season
- Honasa Consumer (Q2 FY27)
Revenue from operations for Q2 FY27: INR 731 Cr, a 35.9% YoY growth from INR 538 Cr in Q2 FY26. Key investor presentation takeaways from Honasa Consumer Ltd's Q
- Emami (Q2 FY27)
Q2FY27 Revenue from Operations:** ₹1,088 crore, up 36% year-on-year . Key investor presentation takeaways from Emami Ltd's Q2 FY27 investor presentation — and h
- Dabur India (Q2 FY27)
Consolidated Revenue: INR 3,563.1 crores in Q2 FY27, up 11.6% YoY (Page 27) . Key investor presentation takeaways from Dabur India Ltd's Q2 FY27 investor presen
- JHS Svendgaard Laboratories (Q2 FY27)
2,077.1 lakhs in the same quarter of 2025, which reflects an approximate year-on-year growth of 10.8%. Key results statement takeaways from JHS Svendgaard Labor
